Should gonadotropin-releasing hormone (GnRH) agonists be offered to all women of reproductive age about to undergo treatment with cyclophosphamide?
Answer from: at Academic Institution
I agree with @Anna Broder's response with a caveat. Ovarian failure is more likely in patients receiving NIH dosing which is 0.5 -1 gram per meter squared of body surface area monthly as opposed to a fixed 500 mg low-dose every 2 weeks. The former in a typical female over six months would be 9 g of ...
Sign in or Register to read more
Answer from: at Academic Institution
I usually discuss family planning with the patient to understand their goals and wishes; fertility preservation may be very important for some while less important for others (e.g., if they already have biological children or do not wish to have biological children in the future). On the other hand,...